A Phase 1/Phase 2, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of SAR444836, an Adeno-associated Viral Vector-mediated Gene Transfer of Human Phenylalanine Hydroxylase, in Adult Participants With Phenylketonuria
Latest Information Update: 08 May 2025
At a glance
- Drugs SAR 444836 (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions
- Sponsors Sanofi
Most Recent Events
- 29 Apr 2025 Protocol has been amended(Time frame for primary endpoind has been changed from From Baseline to Week 96 to From Baseline to Week 260, Secondary outcome measures also amended).
- 29 Apr 2025 Time frame for primary endpoind has been changed from From Baseline to Week 96 to From Baseline to Week 260. Secondary outcome measures also amended.
- 29 Apr 2025 Planned End Date changed from 31 Jul 2027 to 1 Apr 2031.